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Developmental expression of ACE2 in the SHR
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The abnormal development of the intrarenal
renin–angiotensin system (RAS) is thought contribute to
adult-onset hypertension in the spontaneously hypertensive
rat (SHR). Angiotensin-converting enzyme 2 (ACE2) is a novel
enzyme with complementary actions to that of ACE. Recent
studies have shown that ACE2 expression is reduced in the
adult SHR. However, its regulation in pre-hypertensive
animals is unknown. In this study, we examine the
developmental expression of ACE2 in the rodent kidney and
its temporal expression, as it relates to the development of
hypertension in the SHR model. Kidneys from SHR and
normotensive Wistar Kyoto (WKY) rats (n¼ 8–12/group) at
birth, 6 weeks of age, and adulthood (80 days) were
examined. Gene expression and activity of ACE2 were
determined by real-time reverse transcription-polymerase
chain reaction and quenched fluorescence assays,
respectively. Renal expression was localized by in situ
hybridization and immunohistochemistry. The expression
and ACE2 activity are significantly increased in the SHR
kidney at birth. With the onset of hypertension, the tubular
expression of ACE2 falls in SHR compared to WKY and
remains reduced in the adult SHR kidney. Glomerular
expression is paradoxically increased in the SHR glomerulus.
The overall developmental pattern of ACE2 expression in the
SHR kidney is also modified, with declining expression over
the course of renal development. The developmental pattern
of ACE2 expression in the SHR kidney is altered before the
onset of hypertension, consistent with the key role of the RAS
in the pathogenesis of adult-onset hypertension. Further
research is required to distinguish the contribution of these
changes to the development and progression of
hypertension in this model.
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The renin–angiotensin system (RAS) has a central role in the
regulation of blood pressure. In particular, the importance of
the RAS in the development of adult-onset hypertension has
been suggested by studies in the spontaneously hypertensive
rat (SHR). In this model, it has been reported that activation
of the RAS precedes an elevation in blood pressure.1 In
addition, blockade of the RAS for a brief perinatal period
prevents the development of hypertension that normally
occurs in this model at B6 weeks of age.2
Angiotensin-converting enzyme 2 (ACE2) has recently
been identified as a novel enzyme involved in the regulation
of the RAS.3 ACE2 is a carboxypeptidase, converting Ang I to
the nonapeptide angiotensin(1–9) (Ang 1–9) and Ang II to the
angiotensin(1–7) (Ang 1–7) by removing a single amino-acid
residue from the carboxy-terminus of the substrate.4 This
action is distinct and complementary to the dipeptidyl
carboxypeptidase activity of ACE that generates Ang II from
Ang I. ACE2 is thought to represent the major renal source of
Ang 1–7,5,6 a peptide with anti-angiogenic and vasodilatory
actions that antagonize the effects of Ang II.7 Moreover, the
catalytic efficiency of ACE2 for the generation of Ang 1–7 and
its high level of expression implies that ACE2 has an
important regulatory function on basal activation of the
angiotensin receptor by degrading unbound Ang II. ACE2 is
also able to cleave the C-terminal amino acid from vasoactive
des-Arg9-bradykinin to form the inactive peptide, as well as
catabolize dynorphin A, apelin 13, and kinetensin.4
ACE2 is expressed in a variety of tissues such as the heart,
kidney, testis, lungs, gastrointestinal tract, brain, and retina.8
ACE2 is also highly expressed in the uteroplacental complex
(Valdes G, Neves LA, Anton L et al. Hypertension 2004;
22(Suppl 1): S65). Although its precise physiological role
remains to be established, its actions within the RAS suggest a
possible role in the control of blood pressure. We and others
have previously shown that ACE2 expression is decreased in
the hypertensive rats when compared with the normo-
tensive control.9 In addition, the gene for ACE2 maps to
a quantitative trait locus associated with the onset and
severity of hypertension in the SHR.10 However, it is not
clear whether changes in ACE2 expression or activity play
a pathophysiological role in producing hypertension in this
model or are a consequence of increased blood pressure and
subsequent activation of the RAS. Consequently, this study
examines the developmental expression of ACE2 in the
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rodent kidney and its temporal expression, as it relates to the
development of hypertension in the SHR model.
RESULTS
Physiological parameters
At birth, the body weights of SHR and Wistar Kyoto (WKY)
rats were not significantly different. However, postnatal
weight gain was reduced in SHRs. By 6 weeks of age, asso-
ciated with the onset of hypertension in SHR, the mean body
weight was lower in SHR compared to WKY rats. This differ-
ence was more marked in adult rats (Po0.01). Treatment
with ramipril significantly reduced systolic blood pressure
levels in adult SHR rats (Table 1).
Expression of ACE2 and ACE at PN-1
One day following birth, renal expression of the ACE2 gene in
the SHR kidney was increased to almost twice that seen in
WKY animals (SHR vs WKY, Po0.01). At the same time,
ACE gene expression was less than that seen in WKY animals
(Figure 1). Consistent with the pattern of gene expression,
specific ACE2 activity was also higher in SHR kidneys
compared to that in WKY rats at postnatal day 1 (PN-1).
ACE2 protein expression was also higher in SHR at PN-1
as assessed by Western blotting (Figure 1e). When quanti-
fied, these data were identical to the pattern seen for
ACE2 activity. Renal ACE activity was reduced at PN-1 in
SHRs compared to WKY rats, as previously described in this
model.11
Expression of ACE2 and ACE in the 6-week kidney
There was a threefold increase in the gene expression of ACE2
in WKY animals at 6 weeks of age compared to PN-1 (3.5 vs
1.0, Po0.01). However, in SHR, no significant change in
expression was observed between PN-1 and 6 weeks of age.
Moreover, associated with the onset of hypertension at 6
weeks of age, the level of ACE2 gene expression in SHR
kidneys was now approximately half that seen in WKY
kidneys (Figure 1).
A similar overall pattern of gene expression was observed
for ACE, with reduced expression in SHR kidneys compared
to normotensive WKY kidneys at PN-42 (Po0.01). This
reduction in activity was of a similar magnitude to that seen
at birth (B50–60%). Nonetheless, ACE gene expression at
6 weeks in the SHR kidney was still greater than the level
of expression at PN-1.
Despite a difference in ACE2 gene expression between
SHR and WKY kidneys at 6 weeks of age, there was no
significant difference in specific ACE2 enzyme activity.
Nonetheless, renal ACE2 enzyme activity in SHR was reduced
at the 6-week time point compared to that at birth, whereas
activity in the WKY did not change. ACE activity was also
reduced in renal homogenates from SHR compared to WKY
animals (Po0.01; Figure 1).
Expression of ACE2 and ACE in the adult kidney
Consistent with previous reports in the adult SHR kidney, the
level of ACE2 gene expression was half that seen in WKY
animals. The overall level of ACE2 gene expression was
not significantly different from that seen in SHR kidney
at birth. By contrast, renal ACE2 gene expression in
normotensive WKY adults was over threefold above peri-
natal levels (Po0.01). ACE gene expression was also reduced
in the adult SHR kidney, although not to the same extent
as ACE2. In the adult kidney, ACE2 and ACE activities
were also significantly reduced in SHR kidney compared to
the WKY kidney, consistent with the pattern of gene
expression.
Overall, the pattern of expression of ACE and ACE2 was
inversely correlated in normotensive WKY animals (P¼
0.02). However, this correlation was lost in SHR (P¼ 0.6)
Table 1 | Physiological data for experimental models
Strain
(+treatment)
Postnatal
(days)
Number
(n)
Body
weight (g)
Systolic blood
pressure (mm Hg)
WKY 1 9 5.970.5 NA
WKY 42 10 23074 13074
WKY 80 12 35078 13675
SHR 1 8 6.170.6 NA
SHR 42 11 23575 18775*
SHR 80 12 32576* 20978*
SHR 100 8 42576 20978
SHR+R 100 6 43579# 14276#
NA, not applicable; SHR, spontaneously hypertensive rats; WKY, Wistar Kyoto rats.
Data are shown as mean7s.e.m.
*vs WKY at the same time point, Po0.01.
#vs untreated SHR, Po0.01.
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Figure 1 | Gene expression and enzymatic activity of ACE2 and
ACE in renal homogenates. Gene expression of (a) ACE2 and
(b) ACE and enzymatic activity of (c) ACE2 and (d) ACE. Clear
columns are WKY and closed columns are SHR. Data are shown as
mean7s.e.m. *Po0.05 SHR vs WKY; #Po0.05 vs PN-1 (same strain).
Figure 1e shows protein expression by Western blot analysis.
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Localization of ACE2 expression in the rodent kidney
By in situ hybridization, gene expression of ACE2 was
demonstrated in tubules and developing glomeruli in both
SHR and WKY animals (Figures 2 and 3). In the adult kidney,
ACE2 mRNA was predominantly found in the proximal
tubule with less glomerular gene expression compared to
earlier time points.
Consistent with the in situ hybridization findings, ACE2
protein was localized to the apical surface of tubules and
some glomeruli in the PN-1 kidney. Notably, in the sub-
cortical nephrogenic zone, ACE2 expression was focally
seen in comma- and S-shaped structures, consistent with the
proximal tubular differentiation of these cells. At later time
points, ACE2 protein expression was largely limited to the
apical surface of S1–2 proximal tubules and Bowman’s capsule.
This was confirmed by colocalization studies using the brush
border marker, PHA-E lectin (data not shown). Epithelial
cells from the distal tubules and collecting ducts demon-
strated weak cytoplasmic staining. Weak glomerular staining
for ACE2 was also detected in the adult kidneys in endothelial
cells, as well as in larger sized vessels (data not shown),
consistent with our previous findings.12
There was no clear difference in the tubular distribution
of ACE2 between SHR and WKY kidneys. However, the
a b c
d e f
g h i
j k l
g
g
g
g
g
t
g
g
g
Figure 2 | Localization of ACE2 mRNA by in situ hybridization. 35S-labelled riboprobe in light (left panel) and dark field (middle panel) for
(a, b) WKY PN-1, (d, e) PN-42, and (g, h) adult and ACE2 immunoreactivity (dilution of 1/500) (right panel) in (c) WKY PN-1, (f) PN-42, and
(i) adult. g is glomerulus and t is tubule. Original magnification:  850, except for (a–c)  1700. Respective negative controls are shown in the
lower panel: (k) sense (light field), (j) sense (dark field), and (l) pre-absorption with ACE2 peptide. g is glomerulus and t is tubule. Original
magnification:  850, except for (a–c)  1700.
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intensity of glomerular immunostaining was quantita-
tively greater in SHR compared to WKY animals at 6 weeks
(Po0.05) and by adulthood, was at least fourfold greater in
SHR compared to WKY animals (Po0.01). This was despite
an overall reduction in renal ACE2 protein expression in
the adult SHR kidney as demonstrated by Western blot and
ACE2 activity (Figure 1), reflecting the reduction in tubular
expression of ACE2 (Figure 3i). In the adult kidneys,
treatment with ramipril reduced the intensity of glomerular
staining by over fivefold (Po0.01). However, antihyper-
tensive treatment with rampiril had no significant effect on
tubular ACE2 expression (data not shown) and consequently
reduced renal ACE2 expression observed in this model.
DISCUSSION
The abnormal development of the RAS in the SHR kidney
is thought to play an important role in the development of
hypertension. A number of studies have demonstrated the
upregulation of the intrarenal RAS in the early perinatal
period.13–15 For example, previous studies have also shown
that the expression and activity of ACE are reduced in the
developing SHR kidney.11 In addition, renal renin activity
and renal Ang I and Ang II concentrations are elevated before
the onset of hypertension in the SHR kidney.13,14 The
expression of the angiotensin receptor is also increased15
from as early as 4 weeks of age, associated with increased
responsiveness to Ang II. Adding to this literature, we
demonstrate for the first time that, before the onset of hyper-
tension, the expression and activity of the novel carboxy-
peptidase, ACE2, are modified in SHR compared to
normotensive WKY controls.
The finding that renal ACE2 expression and activity are
elevated at birth compared to WKY animals of the same age is
consistent with the hypothesis that there is widespread early
activation of the RAS in this model. However, the precise role
of increased renal ACE2 in pre-hypertensive SHR remains to
be established. ACE2 is postulated to have an important role
counter-balancing the vasoconstrictor arm of the RAS, with
its expression paralleling that of ACE in the kidney. The
possibility that ACE2 is involved in blood pressure modula-
tion in the SHR model has previously been suggested by
studies demonstrating that ACE2 maps to the quantitative
trait loci on the X chromosome, associated with induction of
hypertension.10 It is clear that ACE2 has in vivo activities that
both reduce the renal concentration of Ang II and increase
levels of its endogenous antagonist, Ang 1–7.8,16 Although we
did not measure Ang 1–7 in our study, it has been previously
shown that increased renal ACE2 expression directly parallels
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Figure 3 | Localization of ACE2 mRNA by in situ hybridization. 35S-labelled riboprobe in light (left panel) and dark field (middle panel) for
(a, b) SHR PN-1, (d, e) PN-42, and (g, h) adult and ACE2 immunoreactivity (dilution of 1/500) (right panel) in (c) WKY PN-1, (f) PN-42, and (i) adult.
g is glomerulus and t is tubule. Original magnification:  850, except for (a–c)  1700.
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the increase in Ang 1–7 in the kidney associated with
pregnancy.17 As the development of hypertension in the SHR
appears to be partly driven by Ang II, it is possible that
increased ACE2 expression partly offsets the renal effects of
increased renin, angiotensinogen, and angiotensin receptor
expression in the pre-hypertensive SHR. For example, it is
known that perinatal treatment with ACE inhibitors is able to
attenuate the development of adult hypertension.2 For the
same reason, it is conceivable that the induction of ACE2 is
also protective (albeit ultimately vainly) in the early perinatal
period.
Although changes in the intrarenal RAS may also be
the result of hypertensive changes in the kidney, there is
some evidence to suggest that reduced ACE2 can directly
contribute to hypertension. Support for this hypothesis
comes from the finding that drugs that specifically increase
the expression of ACE2 in the SHR kidney, such as all-trans
retinoic acid, are able to reduce systemic blood pressure levels
in adult animals.9 In our study, we identify a decline in
ACE2 gene and protein expression at least as early as 6 weeks
of age, at the time of onset of hypertension. In addition,
the expression of ACE2 in the hypertensive SHR is not
significantly different from that observed at birth. By
comparison, ACE2 gene expression increases significantly in
the normotensive WKY animals, possibly as part of normal
postnatal tubular development. It has been suggested that
higher ACE2 expression could account for the ‘resistance’ to
hypertension in WKY rats, possibly through increased renal
synthesis of the vasodilatory mediator Ang 1–7.18 Moreover,
it is possible to speculate that the inability of the SHR to
increase further ACE2 expression, in the setting of activation
of the RAS, may constitute a failing of normal counter-
regulatory mechanisms and contribute to hypertension.
Certainly, renal Ang 1–7 levels are reduced and interstitial
Ang II levels are elevated in the adult SHR kidney,14 poten-
tially contributing to tonic renal vasoconstriction.19
In the kidney, ACE2 and ACE are predominantly expres-
sed in the luminal brush border of proximal tubule, which
represents the major source for intratubular and interstitial
Ang II, and the site for its regulation. Notably, the renal
distribution of ACE2 is also similar to Ang 1–7, its major
product.20 In addition, most of the angiotensinogen synthesis
within the kidney is colocalized to proximal tubular cells.
Epithelial cells from the distal tubules and collecting ducts
have also been reported to show weak cytoplasmic staining.21
We have previously reported low-level ACE2 expression in
the rodent glomerulus and specifically in the endothelium of
glomerular capillaries.21 However, the level of expression in
glomeruli is significantly lower than that seen in tubular
sites.21 Nonetheless, there appears to be clear difference
in glomerular staining for ACE2 between SHR and WKY
kidneys, with a paradoxical increase in ACE2 expression
in the SHR glomerulus at both hypertensive time points. At
the same time, tubular expression of ACE2 (and therefore
whole kidney activity) is reduced. We hypothesize that
increased glomerular expression of ACE2 may reflect glome-
rular hypertension and increased shear forces leading to
activation of the local RAS. A similar phenomenon is seen in
diabetes, where reduced tubular ACE2 is accompanied by
increased glomerular ACE2 associated with hyperfiltration
and intraglomerular hypertension.21
The renal actions of ACE2 may be more complex than
simply antagonizing the effects of ACE. For example, ACE2
may also be involved in the metabolism of bradykinin
peptides, both directly through carboxypeptidase activity and
indirectly via the production of Ang 1–7, which stimulates the
production of bradykinin22 and the activity of bradykinin at
the B2 receptor.
23,24 Ang 1–7 also stimulates the production of
nitric oxide25 and vasodilator prostaglandins.26,27 Notably,
bradykinin, nitric oxide, and prostaglandin metabolites have
all been implicated in the development and progression of
hypertension in the SHR model.18,28
The regulated expression of ACE2 in the developing
kidney demonstrated in this study suggests a possible role
in tubulogenesis. In the WKY kidney, both ACE2 gene
expression and catalytic activity peaked at 6 weeks, correlat-
ing with the peak in ACE activity in the developing kidney.
This finding is consistent with previous studies showing the
RAS to be maximally upregulated in the developing kidney
around PN20–40.29 At these times, there is still an active
process of cortical cell proliferation and differentiation.
Furthermore, remodelling of the extracellular matrix occurs
in the papilla even as late as 6 weeks.30 However, any
developmental function for ACE2 remains to be established.
Initial reports on the ACE2 null mouse stated that the
kidneys appeared structurally normal.10 This compares to the
profound disruption of tubular development seen following
deletion of AT1 and AT2 receptor subtypes, angiotensinogen,
and ACE.31–34 Nonetheless, a loss of developmental regula-
tion of ACE2 expression and activity may still be significant
marker of early renal dysfunction in the developing SHR
kidney. Indeed, the increased ACE2 expression in the PN-1
may reflect a premature maturation of the SHR kidney, due
to fetal undernutrition and maternal hypertension, leading to
‘6-week levels of ACE2 expression’ abnormally seen at birth.
This kind of premature renal maturation is thought to be a
key mechanism that underpins the Barker or ‘fetal origins’
hypothesis for adult-onset disease.
In summary, our studies demonstrate that the expression
of ACE2 is developmentally regulated in the rodent kidney,
with the highest expression seen in the developing S1–2 tubule
closely paralleling the renal expression and localization of
ACE. However, this pattern is disturbed in the SHR kidney,
consistent with previous findings showing abnormal deve-
lopmental regulation of the RAS. The expression and activity
of ACE2 are increased in the SHR tubule, before the onset of
hypertension. With the increase in blood pressure at 6 weeks
of age, the tubular expression of ACE2 is reduced in SHR
compared to WKY. Over the course of renal development,
ACE2 expression does not significantly change in the SHR
kidney, whereas at the same time expression is increased
in the WKY. We hypothesize that these changes reflect the
38 Kidney International (2006) 70, 34–41
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compensatory role of ACE2, antagonizing the effects of Ang
II initially in the SHR tubule and subsequently in the
glomerulus following the onset of glomerular hypertension.
Further research is required to distinguish the contribution
of these changes to the development and progression of
hypertension in this model. A better understanding of the
role of ACE2 in normal renal development may be helpful in
elucidating the cause of some pathological conditions that are
postulated to have their genesis in development but do not
display any abnormal phenotype until adulthood, such as
hypertension.
MATERIALS AND METHODS
Animal models
SHR (n¼ 8–12/group, maximum 2 animals/litter) and normotensive
WKY rats (n¼ 8–12/group, maximum 2 animals/litter) were obser-
ved at birth (PN-1), 6 weeks of age (PN-42), and adulthood
(80 days).
In a separate study, PN-42 animals were randomized to receive
the ACE inhibitor ramipril (Aventis, Frankfurt, Germany) at a dose
of 9 mg/l of drinking water for 8 weeks. This dose has previously
been shown to reversibly reduce blood pressure and urinary albumin
excretion.35
During the studies, animals were given access to food and water
ad libitum. All animal procedures were performed in accordance
with guidelines set by the Austin and Repatriation Medical Centre
Ethics Committee and the National Health and Medical Research
Council of Australia. All animals were supplied by Austin Biological
Research Laboratories, Austin and Repatriation Medical Centre,
Melbourne, Australia.
Systolic blood pressure was measured in juvenile and adult
animals using tail-cuff plethysmography. Measurements were
performed in a quiet environment in the morning with animals in
an unanesthetized preheated state.36 At the end of each study period,
animals were killed by cervical dislocation. Kidneys were rapidly
removed, with the right kidney divided and fixed in neutral buffered
formalin for immunohistochemistry, or immersed into OCT
cryogenic mounting medium followed by slow cooling in isopentane
cooled to 701C for subsequent in situ hybridization. The left
kidney was snap-frozen in liquid nitrogen for reverse transcription-
polymerase chain reaction studies.
Isolation of total RNA, synthesis of cDNA, and quantitative
real-time polymerase chain reaction
Snap-frozen cortical kidney samples were homogenized using the
Ultra-Turrax (Janke & Kunkel IKA, Labortechnik, Germany) in
TRIZOL (Life Technologies Inc., Gaithersburg, MD, USA), and total
RNA was isolated. cDNA was synthesized with a reverse transcriptase
reaction using a standard technique (SuperscriptTM First Strand
Synthesis System for RT-PCR, Life Technologies Inc., Gaithersburg,
MD, USA) as previously described.21 To assess genomic DNA conta-
mination, controls without reverse transcriptase were included.
Real-time polymerase chain reaction is a fully quantitative
method for the determination of amounts of mRNA.37 Briefly,
gene-specific 50-oligonucleotide corresponding to the rat ACE
(50-CACCGGCAAGGTCTGCTT), ACE 30-oligonucleotide primer
(50-CTTGGCATAGTTTCGTGAGGAA) and ACE probe (FAM50-CA
ACAAGACTGCCACCTGCTGGTCC-TAMRA), and ACE2 gene-
specific 50-oligonucleotide (50-ACCCTTCTTACATCAGCCCTACTG),
an ACE2 30-oligonucleotide primer (50-TGTCCAAAACCTACCCCAC
ATAT) and ACE2 probe (FAM50-ATGCCTCCCTGCTCATTTGCTT
GGT-TAMRA) were designed using the software program ‘Primer
Express’ (PE Applied Biosystems, Foster City, CA, USA) and real-time
polymerase chain reaction was carried out as previously described.21
18S was used as the endogenous control to ensure equal starting
amounts of cDNA. The normotensive PN-1 group was used as the
calibrator with a given value of 1, with other groups compared with
this calibrator.38
In situ hybridization
ACE2 riboprobe. The 2260 bp rat ACE2 cDNA sequence
(coding for the open reading frame) was inserted in the sense
direction into the BamHI and XhoI sites of the pGEM-7Zf(þ /)
vector (Promega, Madison, WI, USA). The vector was digested with
XbaI and transcribed with SP6 polymerase to provide the antisense
ACE2 riboprobe. The vector was also digested with SacI and
transcribed with the polymerase T7 to provide the sense riboprobe,
which was used as a control for nonspecific hybridization.
The site-specific expression of ACE2 mRNA was determined by
in situ hybridization as follows. Four-micrometer-thick paraffin
kidney sections were hybridized after digestion with PronaseE
at 371C. The hybridization buffer containing 2 104 c.p.m./ml
35S-labelled riboprobe, 0.72 mg/ml yeast RNA, 50% deionized form-
amide, 100 mmol/l dithiothreitol, 10% dextran sulfate, 0.3 mol/l
NaCl, 10 mmol/l Na2HPO4, 10 mmol/l Tris-HCl (pH 7.5), 5 mmol/l
ethylenediaminetetraacetic acid (pH 8.0), 0.02% bovine serum
albumin, 0.02% Ficoll 400, and 0.02% polyvinyl pyrrolidone was
added to each section and incubated at 601C overnight. After
stringent washing with 50% formamide and 2 SSC at 551C, the
slides were air-dried and exposed to BioMax MR film (Kodak) for
3–5 days. Slides were coated in Amersham LM-1 emulsion in a
darkroom, then incubated at 41C in a lightproof container with
desiccant for a period of 2–4 weeks, according to the autoradio-
graphy results. The slides were developed with Kodak D19 developer
for 4 min, 1% acetic acid for 1 min, and Illford Hypan fixative for
4 min, followed by rinsing in distilled water for 15 min. The sections
were then fixed in 4% paraformaldehyde and treated with a
progressive hematoxylin–eosin stain.
Sample preparation and ACE/ACE2 activity assays
Kidney homogenates (n¼ 5/group) were produced by quickly
mincing fresh tissue with a scalpel blade, resuspending in buffer
(10 mM HEPES, 150 mM NaCl, 1 mM ethyleneglycol-bis(b-amino-
ethyl ether)-N,N,N0,N0,-tetraacetic acid, 5 mM MgCl2, and 0.02%
NaN3, pH 7.4, containing 0.5mg/ml pepstatin (Sigma, St Louis, MO,
USA), 0.25 mg/ml leupeptin (Sigma, St Louis, MO, USA), 0.1 mg/ml
benzamidine (Sigma, St Louis, MO, USA), and 0.1 mg/ml bacitracin
(Sigma, St Louis, MO, USA)) and homogenizing at 13 000 r.p.m.
with the Ultra-Turrax (Janke and Kunkel IKA, Labortechnik,
Staufen, Germany), and then centrifuging at 1000 g (41C) for
15 min. The resultant supernatant was harvested and stored in
aliquots at 801C. Before each activity assay, the protein concen-
tration of each sample was determined using a BCA protein assay kit
(Pierce, Rockford, IL, USA).
ACE activity assay
ACE activity was determined following incubation of renal
homogenates with the synthetic ACE-specific substrate, hippuryl
histidylleucine, as adapted from Freidland et al.39 The released
product (His-Leu) was fluorimetrically measured after reaction
with o-phthaldehyde in time-fixed assays. Results were expressed as
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picomole of His-Leu generated per milligram of soluble renal
protein per minute of reaction time (pmol/mg/h).
Quenched fluorescent substrate assay of ACE2 activity
Renal homogenates were incubated with an ACE2-specific quenched
fluorescent substrate ((7-methoxycoumarin-4-yl)-acetyl-Ala-Pro-
Lys(2,4-dinitrophenyl); Auspep, Parkville, Victoria, Australia), as
previously published,6 in triplicate. Assays were performed in black
96-well microtiter plates with 50 mM quenched fluorescent substrate
in a final volume of 200 ml per well ACE2 assay buffer (100 mM Tris,
1 M NaCl, pH 6.5). Final concentration of dimethylsulfoxide (used to
solubilize quenched fluorescent substrate) was 0.7%. Reactions
proceeded at 371C for 30–120 min within a thermostated fMax
fluorescence microplate reader (Molecular Devices, Sunnyvale, CA,
USA), before reading the liberated fluorescence (lex¼ 320 nm,
lem¼ 420 nm). As the quenched fluorescent substrate can be
cleaved by prolyl endopeptidase, a specific inhibitor of this enzyme,
Z-Pro-prolinal (1 mM) was included in all wells. To further validate
this assay, samples were measured in the absence and presence of
a highly specific ACE2 inhibitor, compound No. 16 at 100 nM, which
confirmed the specificity of this technique for measuring ACE2
activity in tissues.40 Using this technique, we report an 11% intra-
assay and 8% inter-day coefficient of variability.
Western blotting and immunohistochemistry
Western blotting for ACE2 protein and immunohistochemical
staining were carried out as previously described,4 using a rabbit
polyclonal anti-ACE2 antibody raised against ACE2 residues
489–508 (antibody kindly donated by Millennium Pharmaceuticals,
Cambridge, MA, USA). To test the specificity of this antibody, 5 mg
of the ACE2 antibody was incubated with 50 mg of the specific ACE2
neutralizing peptide in phosphate-buffered saline for 30 min at
room temperature on a rocking platform. An aliquot of the solution
was then applied to several tissue sections and immunohistochemi-
cal staining was performed as described above (Figure 2l).
Nonspecific staining was tested with 1% non-immunized rabbit
serum. All the sections were analyzed for staining using light
microscopy (Olympus BX-50, Olympus Optical, Tokyo, Japan) and
digitized using a high-resolution camera. Glomerular expression of
ACE2 was determined by separate analysis of glomerular staining
using an image analysis system (Optimas 6.5 software, Media
Cybernetics, USA). For Western blotting, loading was standardized
for the renal expression of b-tubulin.
Statistics
Data are shown as mean7s.e.m. Comparisons were performed
using Statview SE (Brainpower, Calabasas, CA, USA). A P-value of
less than 0.05 was viewed as statistically significant. For quantitative
real-time polymerase chain reaction, values for PN-1 animals
(calibrator) were arbitrarily standardized to 1 and data for other
groups expressed relative to the calibrator value.
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